Drug Details

General Information of the Drug (ID: DR5724)
Name
Ribavirin
Synonyms
ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Copegus; Vilona; Ribavirine; Viramid; Ribamide; Ribamidil; Ribasphere; Ribavirina; Ribavirinum; Ribavirine [INN-French]; Ribavirinum [INN-Latin]; ICN-1229; Ribavirina [INN-Spanish]; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; RTCA; RBV; SCH 18908; UNII-49717AWG6K; Ribamidyl; Ribavirin (Copegus); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; MFCD00058564; Rebetron; Varazid; Ribavirin Capsules; CHEBI:63580; 49717AWG6K; Ribavirin, 98%; 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide; Rebretron; Virazid; Virazide; Ribav; DSSTox_CID_3557; DSSTox_RID_77081; DSSTox_GSID_23557; RTC; 1-(beta-D-Ribofuranosyl)-1,2,4-triazole-3-carboxamide; Cotronak; Ravanex; Ribacine; NSC-163039; C-Virin; DRG-0028; Ribasphere (TN); Virazole (TN); SMR000058315; Copegus (TN); Rebetol (TN); HSDB 6513; SR-01000076112; BRN 0892462; Ribavirine;; NSC163039; Ribavirin [USAN:USP:INN:BAN]; Ribavirin,(S); NCGC00015904-02; Ribavirin, antiviral; CAS-36791-04-5; RG-964; PubChem14187; Ro-20-9963; Spectrum_001826; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 4pb1; ribofluranosyl carboxamide; Prestwick3_000993; Spectrum3_001876; Spectrum4_001252; Spectrum5_002075; R-964; R 9644; SCHEMBL3727; CHEMBL1643; Lopac0_001063; BSPBio_001085; BSPBio_003352; KBioGR_001804; KBioSS_002331; cid_37542; MLS000028486; MLS002222317; DivK1c_000782; SPECTRUM1503938; Ribavirin (JP17/USP/INN); BPBio1_001195; GTPL6842; 1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; DTXSID8023557; HMS502H04; KBio1_000782; KBio2_002328; KBio2_004896; KBio2_007464; KBio3_002854; NINDS_000782; HMS2090L15; HMS2094O09; HMS2098G07; HMS2232P07; HMS3263E08; HMS3715G07; Pharmakon1600-01503938; HY-B0434; ZINC1035331; Tox21_110259; Tox21_200967; Tox21_501063; BDBM50154375; CCG-38985; NSC758650; s2504; SCH-18908; AKOS001715163; Tox21_110259_1; DB00811; GS-3572; LP01063; MCULE-9495128592; NSC-758650; SDCCGSBI-0051033.P004; IDI1_000782; SMP1_000261; NCGC00090726-01; NCGC00090726-03; NCGC00090726-04; NCGC00090726-05; NCGC00090726-06; NCGC00090726-07; NCGC00090726-08; NCGC00090726-09; NCGC00090726-12; NCGC00090726-25; NCGC00258520-01; NCGC00261748-01; 252269-50-4; AS-34178; BCP0726000138; SBI-0051033.P003; AB0068936; AB00430481; EU-0101063; R0077; EN300-59237; D00423; J10190; M-7546; AB00430481-15; AB00430481-16; AB00430481_17; AB00430481_18; 1-beta-Ribofuranosyl-1,2,4-triazole-3-carboamide; 791R045; Q421862; Ribavirin 100 microg/mL in Acetonitrile:Methanol; SR-01000721904; SR-01000076112-2; SR-01000076112-3; SR-01000076112-4; SR-01000721904-2; 1-??-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; BRD-K60369935-001-02-7; BRD-K60369935-001-18-3; SR-01000076112-11; 1-?-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Ribavirin, British Pharmacopoeia (BP) Reference Standard; Z1522567185; 1-(beta -D-ribofuranosyl)-1,2,4-triazole-3-carboxamide; Ribavirin, European Pharmacopoeia (EP) Reference Standard; Ribavirin, United States Pharmacopeia (USP) Reference Standard; Ribavirin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hepatitis C virus infection [ICD-11: 1E51] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C8H12N4O5
PubChem CID
37542
Canonical SMILES
C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N
InChI
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChIKey
IWUCXVSUMQZMFG-AFCXAGJDSA-N
CAS Number
CAS 36791-04-5
ChEBI ID
CHEBI:63580
TTD Drug ID
D0H3WI
DrugBank ID
DB00811
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Jerusalem artichoke + Interferon alpha-2a     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression BAX  Molecule Info 
Pathway MAP
Down-regulation Expression TGFB1  Molecule Info 
Pathway MAP
Down-regulation Expression TP53  Molecule Info 
Pathway MAP
                    In-vivo Model Male albino rats (150-200g) were used in this study.
                    Experimental
                    Result(s)		 Addition of JAT as a supportive regimen to interferon and ribavirin effectively potentiates their anti-fibrotic effects.
Target and Pathway
Target(s) IMP dehydrogenase 1 (IMPDH1)  Molecule Info  [3]
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6842).
Reference 2 Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats. Asian Pac J Cancer Prev. 2016;17(4):1979-85.
Reference 3 Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link